Atrium Therapeutics, Inc. launches as independent RNA cardiology company

Atrium Therapeutics, Inc as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG. The company is led by Kathleen Gallagher, President and Chief Executive Officer (CEO), and begins operations with two precision cardiology candidates, two undisclosed research targets and approximately $270 million in cash and cash equivalents.

"The launch of Atrium Therapeutics marks an important milestone for people living with genetic cardiomyopathies," said Kathleen Gallagher, President and CEO of Atrium Therapeutics. "Patients and families facing these genetically driven rare cardiomyopathies have few if any options that address the underlying cause. Building on Avidity's pioneering work in targeted RNA delivery, Atrium is positioned to advance precision medicines designed to directly target the biologic drivers of cardiac disease. Atrium has the opportunity to help pave the way for a new era for RNA therapies in precision cardiology."

"As Atrium Therapeutics embarks on a new chapter today, I am incredibly proud of the team's commitment to advancing groundbreaking science for people with genetically driven cardiomyopathies," said Sarah Boyce, Chair of Atrium Therapeutics' board of directors and former CEO of Avidity. "Precision cardiology is an area of immense opportunity, and I am confident the Atrium Therapeutics team's experiences in rare disease, drug development and RNA therapeutics and patient-focused approach will urgently move its pipeline forward."